Exelixis
EXEL
#1660
Rank
S$13.72 B
Marketcap
$48.06
Share price
1.26%
Change (1 day)
68.06%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total debt

Total debt on the balance sheet as of September 2024 : S$0.25 Billion

According to Exelixis's latest financial reports the company's total debt is S$0.25 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Exelixis - Total debt on balance sheet (from 2000 to 2024)

Total debt by year

Year Total debt Change
2023-12-31S$0.25 B-1.6%
2022-12-31S$0.25 B267.8%
2021-12-31S$69.31 M6.74%
2020-12-31S$64.93 M0.32%
2019-12-31S$64.72 M217.64%
2018-12-31S$20.37 M1.99%
2017-12-31S$19.97 M-92.7%
2016-12-31S$0.27 B-53.7%
2015-12-31S$0.59 B25.34%
2014-12-31S$0.47 B7.21%
2013-12-31S$0.43 B7.15%
2012-12-31S$0.41 B74.66%
2011-12-31S$0.23 B-12.46%
2010-12-31S$0.26 B140.23%
2009-12-31S$0.11 B-33.58%
2008-12-31S$0.16 B-3.75%
2007-12-31S$0.17 B-6.26%
2006-12-31S$0.18 B-24.73%
2005-12-31S$0.24 B3.09%
2004-12-31S$0.24 B27.37%
2003-12-31S$0.18 B47.12%
2002-12-31S$0.12 B41.59%
2001-12-31S$90.6 M249.68%
2000-12-31S$25.91 M17.01%
1999-12-31S$22.14 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
S$28.49 B 10,953.10%๐Ÿ‡ฌ๐Ÿ‡ง UK
S$33.75 B 12,994.04%๐Ÿ‡ซ๐Ÿ‡ท France
S$50.10 B 19,333.77%๐Ÿ‡บ๐Ÿ‡ธ USA
S$68.15 B 26,334.21%๐Ÿ‡บ๐Ÿ‡ธ USA
S$80.08 B 30,961.74%๐Ÿ‡บ๐Ÿ‡ธ USA
S$47.40 B 18,286.18%๐Ÿ‡บ๐Ÿ‡ธ USA
S$91.05 B 35,219.50%๐Ÿ‡บ๐Ÿ‡ธ USA
S$4.71 M-98.17%๐Ÿ‡บ๐Ÿ‡ธ USA
S$51.28 M-80.11%๐Ÿ‡บ๐Ÿ‡ธ USA